NASDAQ · PHAT
Healthcare · Biotechnology
$8.16
Down-$0.47 (-5.76%)
Updated Sep 16, 2026, 9:43 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PHAT closed at $8.16 after 20 trading sessions, down 11.78% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $8.63 | $8.655 | $8.10 | $8.16 | 1.64M |
| Sep 14, 2026 | $8.45 | $8.8299 | $8.35 | $8.68 | 1.32M |
| Sep 11, 2026 | $8.40 | $8.52 | $8.07 | $8.36 | 1.39M |
| Sep 10, 2026 | $8.50 | $8.545 | $8.29 | $8.37 | 1.09M |
| Sep 9, 2026 | $9.32 | $9.32 | $8.64 | $8.67 | 1.11M |
| Sep 8, 2026 | $9.42 | $9.65 | $9.22 | $9.43 | 1.03M |
| Sep 4, 2026 | $8.99 | $9.55 | $8.8901 | $9.50 | 1.24M |
| Sep 3, 2026 | $9.30 | $9.3113 | $8.984 | $9.05 | 663.06K |
| Sep 2, 2026 | $9.45 | $9.7296 | $9.05 | $9.26 | 932.65K |
| Sep 1, 2026 | $9.55 | $9.675 | $9.15 | $9.39 | 885.49K |
| Aug 31, 2026 | $9.17 | $9.695 | $9.0401 | $9.57 | 1.21M |
| Aug 28, 2026 | $8.89 | $9.305 | $8.7816 | $9.18 | 894.43K |
| Aug 27, 2026 | $8.77 | $8.99 | $8.545 | $8.94 | 1.05M |
| Aug 26, 2026 | $8.78 | $8.865 | $8.571 | $8.77 | 800.62K |
| Aug 25, 2026 | $8.75 | $8.94 | $8.64 | $8.80 | 748.61K |
| Aug 24, 2026 | $8.88 | $8.92 | $8.51 | $8.66 | 992.81K |
| Aug 21, 2026 | $8.63 | $8.896 | $8.59 | $8.87 | 979.41K |
| Aug 20, 2026 | $9.25 | $9.30 | $8.40 | $8.60 | 1.41M |
| Aug 19, 2026 | $9.42 | $9.70 | $9.31 | $9.32 | 781.95K |
| Aug 18, 2026 | $9.33 | $9.745 | $9.175 | $9.25 | 976.46K |
The latest Smart Investors Daily articles mentioning PHAT.
PHAT research
Company profile and research snapshot.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Market Perform | — |
| Aug 17, 2026 | Barclays | Overweight | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 9, 2026
Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI).
SeekingAlpha · Sep 9, 2026
Phathom Pharmaceuticals is targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Read more on PHAT stock here.
Benzinga · Sep 9, 2026
Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
Benzinga · Aug 17, 2026
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PHAT.
